The effect of supplementation of vitamin D on hyperlipidemia and bone mass in the pediatric with obesity

Abstract

Objective Vitamin D deficiency is known to be a significant factor in metabolic diseases such as obesity and diabetes. However, there is currently a lack of evidence regarding the effects of vitamin D on hyperlipidemia, glucose metabolism, and bone mass in pediatric patients with obesity. Methods Our study aimed to determine the relationship between Serum 25(OH)D and metabolic syndrome, as well as investigate the effect of Vitamin D3 supplementation on hyperlipidemia, glucose metabolism, and bone mass in pediatric patients with obesity. We conducted a cross-sectional study between January 2018 and January 2020, with a total of 723 children invited to participate. Of these, 283 were in the supplemented group (SG) and 440 were in the placebo group (PG). We evaluated blood pressure, fasting glucose, high-density lipoprotein, total cholesterol, low-density lipoprotein, and bone mineral density (BMD) among all subjects. Results We found that cholesterol, triglyceride, and glucose levels were strongly associated with 25(OH)D3 levels at baseline. After vitamin D3 supplementation, we observed a significant increase in body mass index (BMI) (P=0.02) and serum 25(OH)D3(P<0.01) levels in the vitamin D3 group compared to the placebo group. Additionally, serum lipids such as total cholesterol(P<0.01), HDL-c(P<0.01), Total cholesterol/HDL-c (P<0.01), LDL-c/HDL-c (P<0.01), Triglycerides/HDL-c(P<0.01) were significantly decreased in the Vit D group compared to the placebo group. Serum 25(OH)D was inversely associated with cholesterol, triglycerides, and fasting glucose. Conclusion Our results suggest that vitamin D3 supplementation can enhance the beneficial effect of hyperlipi